Comparative Effectiveness of Lisocabtagene Maraleucel (Liso-cel) in PILOT in Patients (Pt) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL) for Whom Transplant Was Not Intended (TNI) Versus Conventional Second-Line (2L) Chemotherapy Regimens in the Real World

被引：0

作者：

Ghosh, Nilanjan ^{[1
]}

Sehgal, Alison R. ^{[2
]}

Liu, Fei Fei ^{[3
]}

Kostic, Ana ^{[4
]}

Crotta, Alessandro ^{[5
]}

Peng, Lily ^{[4
]}

De Benedetti, Marc ^{[3
]}

Gordon, Leo, I ^{[6
]}

机构：

[1] Atrium Hlth, Levine Canc Inst, Charlotte, NC USA

[2] Univ Pittsburgh, Hillman Canc Ctr, Med Ctr, Pittsburgh, PA USA

[3] Bristol Myers Squibb, Princeton, NJ USA

[4] Bristol Myers Squibb, Seattle, WA USA

[5] Celgene, Boudry, Switzerland

[6] Northwestern Univ, Robert H Lurie Comprehens Canc Ctr, Feinberg Sch Med, Chicago, IL USA

来源：

BLOOD | 2022年 / 140卷

关键词：

D O I：

10.1182/blood-2022-159686

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

705

引用

页码：10430 / 10431

页数：2

共 50 条

[21] Qualitative Analysis of the Treatment Experience and Well-Being of Patients with Relapsed/Refractory (R/R) Large B-Cell Lymphoma (LBCL) Enrolled in 2 Trials of Lisocabtagene Maraleucel (liso-cel) during the Initial Stages of Therapy
Siddiqi, Tanya
Jaeger, Ulrich
Moshkovich, Olga
Devlen, Jennifer
Miera, Matthew
Williams, Agnes
Hasskarl, Jens
Liu, Fei Fei
Braverman, Julia
Salles, Gilles
BLOOD, 2020, 136
[22] USE OF EXTERNAL CONTROL DATA TO ADJUST FOR TREATMENT SWITCHING IN COST-EFFECTIVENESS ANALYSES: LISOCABTAGENE MARALEUCEL (LISO-CEL) VERSUS STANDARD OF CARE (SOC) IN SECOND-LINE RELAPSED OR REFRACTORY LARGE B-CELL LYMPHOMA
Chandler, C.
Liu, F. F.
Klijn, S.
Elsada, A.
Proskorovsky, I
VALUE IN HEALTH, 2023, 26 (12) : S407 - S408
[23] Lisocabtagene Maraleucel as Second-Line Therapy for R/R Large B-Cell Lymphoma in Patients Not Intended for Hematopoietic Stem Cell Transplant: Final Analysis of the Phase 2 PILOT Study
Sehgal, Alison R.
Hoda, Daanish
Riedell, Peter A.
Ghosh, Nilanjan
Hamadani, Mehdi
Hildebrandt, Gerhard
Godwin, John E.
Reagan, Patrick M.
Wagner-Johnston, Nina
Essell, James
Nath, Rajneesh
Solomon, Scott R.
Champion, Rebecca
Licitra, Edward
Fanning, Suzanne
Gupta, Neel K.
Chow, Victor A.
Yuan, Brenda
Yang, Zhi
Ogasawara, Ken
Thorpe, Jerill
Gordon, Leo I.
BLOOD, 2023, 142
[24] Costs of Postinfusion Monitoring By Site of Care for Patients with Relapsed/Refractory (R/R) Large B-Cell Lymphoma (LBCL) Who Received Third-Line or Later Treatment with Lisocabtagene Maraleucel (liso-cel) in the Transcend NHL 001 and Outreach Trials
Palomba, M. Lia
Jun, Monika P.
Garcia, Jacob
Lymp, James
McGarvey, November
Gitlin, Matthew
Pelletier, Corey
Nguyen, Andy
BLOOD, 2020, 136
[25] Characterization of cytokine release syndrome (CRS) and neurological events (NEs) in the phase I TRANSCEND NHL 001 trial of lisocabtagene maraleucel (liso-cel) for patients (pts) with relapsed/refractory (R/R) large B-cell lymphoma (LBCL).
Abramson, Jeremy S.
Siddiqi, Tanya
Gordon, Leo, I
Lunning, Matthew Alexander
Wang, Michael
Arnason, Jon E.
Mehta, Amitkumar N.
Purev, Enkhee
Maloney, David G.
Andreadis, Charalambos
Sehgal, Alison R.
Solomon, Scott R.
Ghosh, Nilanjan
Albertson, Tina M.
Garcia, Jacob
Kostic, Ana
Li, Daniel
Kim, Yeonhee
Palomba, Maria Lia
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
[26] Outpatient Treatment with Lisocabtagene Maraleucel (liso-cel) in Three Ongoing Clinical Studies in Relapsed/Refractory (R/R) B Cell Non-Hodgkin Lymphoma (NHL), Including Second-Line Transplant Ineligible Patients: Transcend NHL 001, Outreach, and PILOT
Bachier, Carlos R.
Palomba, Maria Lia
Abramson, Jeremy S.
Andreadis, Charalambos
Sehgal, Alison R.
Godwin, John
Hildebrandt, Gerhard C.
Siddiqi, Tanya
Stevens, Don
Farazi, Thalia
Kostic, Ana
Trede, Nikolaus S.
Wang, Lei
Lymp, James
Thelen, Tennille
Ogasawara, Ken
Maloney, David G.
BLOOD, 2019, 134
[27] Results from Outreach: A Phase 2 Study of Lisocabtagene Maraleucel (Liso-cel) Administered As Outpatient (Outpt) or Inpatient (Inpt) Treatment in the Community/Nonuniversity Setting in Patients (Pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL)
Linhares, Yuliya
Freytes, Cesar
Cherry, Mohamad
Bachier, Carlos
Maris, Michael
Hoda, Daanish
Varela, Juan Carlos
Bellomo, Courtney
Cross, Scott
Essell, James
Fanning, Suzanne
Terebelo, Howard
Yimer, Habte
Courtright, Jay
Sharman, Jeff P.
Vedal, Min
Mailley, Connor
Espinola, Ricardo
Mattar, Bassam
BLOOD, 2022, 140 : 10416 - 10418
[28] Matching-Adjusted Indirect Comparison (MAIC) of Axicabtagene Ciloleucel (Axi-Cel) and Lisocabtagene Maraleucel (Liso-Cel) in Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL) After Two or More Prior Lines of Therapy
Oluwole, Olalekan O.
Chen, Jenny M. H.
Chan, Keith
Patel, Anik R.
Jansen, Jeroen P.
Keeping, Sam
Bashir, Zahid
Zheng, Yan
Snider, Julia
Locke, Frederick L.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S388 - S388
[29] Outpatient Treatment with Lisocabtagene Maraleucel (liso-cel) in 3 Ongoing Clinical Studies in Relapsed/Refractory (R/R) Large B Cell Non-Hodgkin Lymphoma (NHL), Including Second-Line Transplant Noneligible (TNE) Patients: Transcend NHL 001, Outreach, and PILOT
Bachier, Carlos R.
Palomba, M. Lia
Abramson, Jeremy S.
Andreadis, Charalambos
Sehgal, Alison
Godwin, John
Hildebrandt, Gerhard C.
Siddiqi, Tanya
Stevens, Don
Farazi, Thalia
Kostic, Ana
Trede, Nikolaus S.
Wang, Lei
Lymp, James
Thelen, Tennille
Ogasawara, Ken
Maloney, David G.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2020, 26 (03) : S25 - S26
[30] Two-Year Follow-up of Transcend NHL 001, a Multicenter Phase 1 Study of Lisocabtagene Maraleucel (liso-cel) in Relapsed or Refractory (R/R) Large B-Cell Lymphomas (LBCL)
Abramson, Jeremy S.
Palomba, M. Lia
Gordon, Leo I.
Lunning, Matthew A.
Wang, Michael
Arnason, Jon E.
Purev, Enkhtsetseg
Maloney, David G.
Andreadis, Charalambos
Sehgal, Alison R.
Solomon, Scott R.
Ghosh, Nilanjan
Kostic, Ana
Kim, Yeonhee
Ogasawara, Ken
Dehner, Christine
Siddiqi, Tanya
BLOOD, 2021, 138

← 1 2 3 4 5 →